The present invention relates to methods for treating psoriasis and other indications by inhibiting leptin activity.

Disclosed are methods for treating Set1/COMPASS-associated cancers characterized by expression of Set1B/COMPASS. The methods typically include administering a therapeutic amount of an inhibitor of the Set1B/COMPASS pathway and/or an agonist for a target that is negatively regulated by the Set1B/COMPASS pathway.

A glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof are disclosed.

A glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof are disclosed.

The present invention relates to a glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof.

The present invention relates to a glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof.

The invention comprises a ready to use film dosage form comprising microemulsion of an Active Pharmaceutical Ingredient embedded or immobilized in a thin polymeric matrix as a double microemulsion and a process of making the same. The microemulsion in the film dosage form of this invention is capable of being absorbed through mucosal route. The process of making the film dosage of this invention comprises steps of forming a film forming dispersion containing film forming polymers, excipients and microemulsion of active pharmaceutical ingredient, casting the same in the form of a film and drying the cast of the film being carried out by means of drying conditions that suit to retain stability of the active pharmaceutical ingredient being selected such that drying of the film is achieved retaining the moisture trapped in the microemulsion embedded in the polymeric film.

A peptide and a peptide complex of the present invention exhibit an anti-obesity effect by inhibiting fat accumulation and decomposing already accumulated fat, and exhibit an excellent effect with respect to diabetes by effectively reducing blood sugar. The peptide and the peptide complex of the present invention decrease the expression of PPAR, ACC, and aP2, which are adipogenic markers, increase the expression of pHSL, AMPK-1, CGI-58, and ATGL, which are lipolytic factors, and reduce the size of fat cells and blood cholesterol values. The peptide and the peptide complex of the present invention, which have excellent activity and safety, can be advantageously applied to drugs and quasi-drugs.

Methods for controlling body weight and/or appetite in a subject are disclosed. In some embodiments, the methods involve administering to an overweight or obese subject an effective amount of a first agent comprising MIC-1, a MIC-1 agonist and/or a MIC-1-inducing agent, and a second agent comprising leptin and/or a leptin agonist, for the purpose of achieving weight loss. In other embodiments, the methods involve administering to an anorexic or cachectic subject an effective amount of a MIC-1-inhibiting agent and a leptin-inhibiting agent, for the purpose of increasing body weight and/or appetite in a subject.

Methods for controlling body weight and/or appetite in a subject are disclosed. In some embodiments, the methods involve administering to an overweight or obese subject an effective amount of a first agent comprising MIC-1, a MIC-1 agonist and/or a MIC-1-inducing agent, and a second agent comprising leptin and/or a leptin agonist, for the purpose of achieving weight loss. In other embodiments, the methods involve administering to an anorexic or cachectic subject an effective amount of a MIC-1-inhibiting agent and a leptin-inhibiting agent, for the purpose of increasing body weight and/or appetite in a subject.